TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02113995

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACERTO protocol vs Traditional care
Description: Three sample blood collections were performed, being one in the anesthesic induction and the others in the next 24 to 48 hours. The blood was sent to the laboratory for dosages of glucose, insulin, C-reactive protein, albumin, prealbumin, alpha 1 acid glycoprotein and interleukin 6. During the anesthesic induction we also collected blood for analize glycosylated hemoglobin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACERTO protocol vs Traditional care
Description: Three sample blood collections were performed, being one in the anesthesic induction and the others in the next 24 to 48 hours. The blood was sent to the laboratory for dosages of glucose, insulin, C-reactive protein, albumin, prealbumin, alpha 1 acid glycoprotein and interleukin 6. During the anesthesic induction we also collected blood for analize glycosylated hemoglobin.
Study: NCT01692210

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: After induction of general anesthesia, a loading dose of dexmedetomidine (1 mcg/kg) given in 15 min followed by an infusion of the same medication at a rate of 0.4 - 0.7 mcg/kg/hour.
Study: NCT03126006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NSPT plus oral hygiene
Description: Non-surgical periodontal therapy under local anesthesia to remove plaque and calculus

Intervention type: OTHER
Group type: OTHER
Intervention: Oral hygiene alone
Description: It includes pregnant women (with periodontal disease) who will not be given any mechanical treatment such as non-surgical periodontal therapy during pregnancy. However, oral hygiene instructions will be given.
Study: NCT02043951

Intervention type: DEVICE
Intervention: Lutonix Drug Coated Balloon Catheter
Study: NCT01537874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: 30 - 45 minutes in-person session to deliver results of nicotine air monitor and discuss home smoking ban using motivational interview techniques

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual best practices
Description: Standard care delivered using informational materials
Study: NCT03335423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral metformin
Description: The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous metformin
Description: The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral codeine and oral metformin
Description: The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral codeine and intravenous metformin
Description: The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
Study: NCT03409107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat (GSK1278863)
Description: Daprodustat will be available as 9 millimeter (mm) or 7 mm film-coated tablets. Daprodustat will be administered once daily via oral route and can be taken without regard to food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daprodustat matching placebo will be available as 9 mm or 7 mm film coated tablets. Placebo will be administered once daily via oral route and can be taken without regard to food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron therapy
Description: Iron therapy will be administered if ferritin is \<50 Nano gram per milliliter and/or TSAT is \<15 percent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iron therapy
Description: Iron therapy will be administered if ferritin is \<50 Nano gram per milliliter and/or TSAT is \<15 percent.
Study: NCT01953874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MV ASV
Description: Minute ventilation-targeted servo-ventilation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Medical Treatment
Description: Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Medical Treatment
Description: Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
Study: NCT04277650

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Machine learning algorithm
Description: machine learning directed identification of radiotherapy or chemoradiotherapy patients at high-risk for emergency department acute care and/or hospitalization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Machine learning algorithm
Description: machine learning directed identification of radiotherapy or chemoradiotherapy patients at high-risk for emergency department acute care and/or hospitalization
Study: NCT04924686

Intervention type: OTHER
Intervention: Observational studies, no intervention
Description: Observational studies, no intervention

Intervention type: OTHER
Intervention: Observational studies, no intervention
Description: Observational studies, no intervention
Study: NCT03954158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment 2%
Description: BID regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: BID regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment 2%
Description: QD regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: QD regimen
Study: NCT00841347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: habitual sleep length period + extended sleep length period
Description: On obese group, realisation of an habitual sleep length period followed by an extended sleep length period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: extended sleep length period + habitual sleep length period
Description: On obese group, realisation of an extended sleep length period followed by an habitual sleep length period
Study: NCT04281901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet- and extracellular vesicle-rich plasma
Description: ear wick soaked in platelet- and extracellular vesicle-rich plasma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard conservative treatment
Description: standard conservative measures, including antimicrobials, antiseptics and aural toilette for treating a chronically inflamed radical cavity.
Study: NCT02809859

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fisher & Paykel Healthcare CPAP Device
Description: Fisher \& Paykel Healthcare CPAP Device
Study: NCT03357133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: Tirofiban Injection after the alteplase intravenous thrombolysis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alteplase
Description: Only alteplase intravenous thrombolysis
Study: NCT02830958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: The Kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting. Latex-free and wearable for days at a time, Kinesio® Tex Tape is safe for populations ranging from pediatric to geriatric, and successfully treats a variety of orthopedic, neuromuscular, neurological and other medical conditions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: No intervention. Uses of an ordinary tape
Study: NCT02721524

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tricuspid Annuloplasty
Description: Patients will undergo repair of tricuspid regurgitation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tricuspid Annuloplasty
Description: Patients will undergo repair of tricuspid regurgitation
Study: NCT02925260

Intervention type: OTHER
Intervention: MRI with ileal pouch contrast and enema.
Description: Pre enema 20mg IV or IM Hyoscine Butylbromide (Buscopan) Pre enema Small Field of View (SFOV) T2 sagittal series Pre enema SFOV T2 axial series Pre enema SFOV T1 sagittal series (fat suppressed) Pre enema SFOV T1 axial series (fat suppressed) Enema infiltration started During enema filling Dynamic T1 sagittal single image, fat suppressed, aligned on pouch-anal anastomosis During enema filling T1 sagittal series (fat suppressed) During enema filling T1 axial series (fat suppressed) Jelly infiltrated and held Evacuating series Oblique sagittal T2 evacuating series of the mid and distal pouch, aligned to the pouch-anal anastomosis
Study: NCT03440762

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: AF awareness education
Description: Participants will receive education about a description of AF, complications, recognition of signs and symptoms of AF, pulse taking, and how to recognize an irregular pulse
Study: NCT02156895

Intervention type: DRUG
Intervention: Axitinib
Description: based on Axitinib approval
Study: NCT03290755

Intervention type: BEHAVIORAL
Intervention: semi-directed interviews
Description: semi-directed interviews in order to collect socio-behavioral data
Study: NCT00638742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost
Description: latanoprost 0.005% (1.5 ug) will be administered. A single drop of latanoprost 0.005% will be instilled into both eyes by the investigator.
Study: NCT00212472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Factor VIII concentrates
Description: To be determined at the discretion of the investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Factor VIII concentrates
Description: To be determined at the discretion of the investigator.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose treatment
Description: 50 FVIII u/kg three times a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-dose treatment
Description: 200 FVIII u/kg per day.
Study: NCT03380702

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: whitening photoactivation gel
Description: 35 subjects in active comparator group

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 35 subjects in placebo comparator group
Study: NCT01624857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
Study: NCT02521558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The investigators are interested in how practicing memory tasks can improve memory in patients with MCI and with AD. Specifically, patients will perform a set of cognitive rehabilitation tasks designed to train memory in order to determine if these tasks are effective in improving memory or slowing the progression of Alzheimer's disease. Patients will practice memory tasks for about an hour daily, for a total duration of 6 months. A research assistant or clinician will conduct weekly check-ins with each participant assess whether or not participants in the Intervention Group exhibit weekly improvements and to determine if patients are regularly adhering to the tasks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The Control Group will not receive any cognitive rehabilitation tasks for a six month period. Instead, they will simply be given booklets of puzzles (e.g., word search, number puzzles, etc.) to work on for the duration of 6 months.~A research assistant or clinician will conduct weekly check-ins with each participant assess whether or not participants in the control group feel like they are benefiting from the puzzles.~Participants in the Control Group will be given a standard battery of neuropsychological tests prior to the the puzzles and after the puzzles to assess any changes in memory, language, attention, and executive functioning.
Study: NCT02750475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunscreen Sport Lotion (BAY987516)
Description: 50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB# Y65-110)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated Skin
Description: This site is patched without treatment as irradiated control
Study: NCT04408547

Intervention type: DEVICE
Intervention: embryo transfer catheter
Description: undergoing embryo transfer

Intervention type: DEVICE
Intervention: embryo transfer catheter
Description: undergoing embryo transfer
Study: NCT01311362

Intervention type: DRUG
Intervention: St. Johns wort
Description: * Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~* Administration of SJW: 300 mg p.o. three times a day (t.i.d.) on days 11-20

Intervention type: DRUG
Intervention: St. Johns wort
Description: * Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~* Administration of SJW: 300 mg p.o. three times a day (t.i.d.) on days 11-20
Study: NCT00458679

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS VACCINE
Description: Patients will receive a fixed dose (2 x 10\^7) of IL-2 secreting B-cells together with (2 x 10\^7)hCD40L expressing B-cells. They will receive 18 deltoid injections over 52 weeks.
Study: NCT02826018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-HBV
Description: Ascending doses of ALN-HBV by subcutaneous (sc) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Calculated volume to match active comparator
Study: NCT03499379

Intervention type: DEVICE
Intervention: Mirena
Description: A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.

Intervention type: DEVICE
Intervention: Paraguard
Description: A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
Study: NCT02909023

Intervention type: BIOLOGICAL
Intervention: blood samples are performed to measure active T cellular immune response during a routine visit
Description: During the visit 1 (V1), after signing the informed consent, 40 mL blood sampling are carried out and analyzed with the test ELISPOT to check if the patient shows a T immune response against HBV.~The visit 2 will be performed 4-8 weeks (depending on the availability of the patient) following V1 visit, in case the patient shows an immune response against HBV positive T following the sample taken at V1. 150 ml blood sampling are carried out at this visit.
Study: NCT01572246

Intervention type: OTHER
Intervention: Optimal placement of return pad
Description: The ESU return pad will be placed in an optimal position in order to direct ME current away from the ICD pulse generators.
Study: NCT03091881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron 0.1 MG/ML
Description: Granisetron 0.1 MG/ML Will be given 10 min before spinal block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos will be given 10 min before spinal block
Study: NCT01961596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooling Ice Spray
Description: A bursts of the Cooling Ice Spray over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: A bursts of the water spray (room temperature over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.
Study: NCT00827593

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard behavioral weight loss treatment
Description: Participants will receive 12 months of university-based behavioral weight loss treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Watchers
Description: Participants will receive 12 months of Weight Watchers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined Treatment
Description: Participants will receive university-based behavioral weight loss treatment followed by Weight Watchers
Study: NCT00723424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 50 mg, for 13 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5672
Description: 50 mg, for 13 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: 0.5mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: 0.5mg dose
Study: NCT02306265

Intervention type: DEVICE
Group type: OTHER
Intervention: FFDM
Description: 2D imaging of the breast using Full-Field Digital Mammography (FFDM) device

Intervention type: DEVICE
Group type: OTHER
Intervention: DBT
Description: 3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device
Study: NCT03262090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2ug/kg dexmedetomidine
Description: subjects were randomly assigned to receive 0.2ug/kg intravenous dexmedetomidine before skin incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.4ug/kg dexmedetomidine
Description: subjects were randomly assigned to receive 0.4ug/kg intravenous dexmedetomidine before skin incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.6ug/kg dexmedetomidine
Description: subjects were randomly assigned to receive 0.6ug/kg intravenous dexmedetomidine before skin incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.8ug/kg dexmedetomidine
Description: subjects were randomly assigned to receive 0.8ug/kg intravenous dexmedetomidine before skin incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.0ug/kg dexmedetomidine
Description: subjects were randomly assigned to receive 1.0ug/kg intravenous dexmedetomidine before skin incision
Study: NCT04524728

Intervention type: DRUG
Intervention: Palbociclib
Description: tablets

Intervention type: DRUG
Intervention: Palbociclib
Description: tablets

Intervention type: DRUG
Intervention: Letrozole 2.5mg
Description: tablets

Intervention type: DRUG
Intervention: Fulvestrant
Description: intramuscolar injections
Study: NCT03191357

Intervention type: OTHER
Intervention: n/a observational
Description: Observational study

Intervention type: OTHER
Intervention: n/a observational
Description: Observational study

Intervention type: OTHER
Intervention: n/a observational
Description: Observational study

Intervention type: OTHER
Intervention: n/a observational
Description: Observational study
Study: NCT06265883

Intervention type: PROCEDURE
Intervention: Len+DEB-TACE+HAIC
Description: Patients received TACE with drug-eluting beads and FOLFOX-HAIC. DEB-TACE and/or HAIC was repeated for viable tumors demonstrated by follow-up imaging in patients without worsening liver function or contraindications. Lenvatinib was orally administered at a dose of 12 mg/day (bodyweight 60 kg) or 8mg/day (bodyweight \<60 kg). It was initiated within 7 days after the first DEB-TACE or DEB-TACE+HAIC and continued until unacceptable toxicity or disease progression occurred.

Intervention type: PROCEDURE
Intervention: Len+DEB-TACE
Description: Patients received TACE with drug-eluting beads. DEB-TACE was repeated for viable tumors demonstrated by follow-up imaging in patients without worsening liver function or contraindications. Lenvatinib was orally administered at a dose of 12 mg/day (bodyweight 60 kg) or 8mg/day (bodyweight \<60 kg). It was initiated within 7 days after the first DEB-TACE or DEB-TACE+HAIC and continued until unacceptable toxicity or disease progression occurred.
Study: NCT03940235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen deprivation therapy (ADT)
Description: SBRT + ADT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: SBRT to all radiological documented lesions (bone or lymphnodes)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT to all radiological documented lesions (bone or lymphnodes)